ARID1A is altered in 9.46% of malignant solid tumor patients with ARID1A Loss present in 0.21% of all malignant solid tumor patients [4].

ARID1A Loss is an inclusion criterion in 18 clinical trials for malignant solid tumor, of which 15 are open and 3 are closed. Of the trials that contain ARID1A Loss and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 5 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

ARID1A is altered in 2.84% of prostate adenocarcinoma patients with ARID1A Loss present in 0.03% of all prostate adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ARID1A Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [5].

ARID1A is altered in 2.81% of prostate carcinoma patients with ARID1A Loss present in 0.03% of all prostate carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ARID1A Loss and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

ARID1A is altered in 6.33% of breast carcinoma patients with ARID1A Loss present in 0.21% of all breast carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ARID1A Loss and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [5].

ARID1A is altered in 6.45% of ovarian carcinoma patients with ARID1A Loss present in 0.15% of all ovarian carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ARID1A Loss and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 4.55% of primary peritoneal carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 4 clinical trials for primary peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ARID1A Loss and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [5].

ARID1A is altered in 9.2% of non-hodgkin lymphoma patients with ARID1A Loss present in 0.81% of all non-hodgkin lymphoma patients [4].

ARID1A Loss is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

ARID1A is altered in 13.66% of adenocarcinoma of the gastroesophageal junction patients with ARID1A Loss present in 0.33% of all adenocarcinoma of the gastroesophageal junction patients [4].

ARID1A Loss is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain ARID1A Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

ARID1A is altered in 9.79% of cervical carcinoma patients with ARID1A Loss present in 0.3% of all cervical carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [5].

ARID1A is altered in 10.87% of colorectal carcinoma patients with ARID1A Loss present in 0.24% of all colorectal carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A Loss and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 5.45% of fallopian tube carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A Loss and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 11.2% of diffuse large B-cell lymphoma patients with ARID1A Loss present in 0.99% of all diffuse large B-cell lymphoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 41.6% of endometrial carcinoma patients with ARID1A Loss present in 0.63% of all endometrial carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 55.86% of endometrial endometrioid adenocarcinoma patients with ARID1A Loss present in 0.6% of all endometrial endometrioid adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for endometrial endometrioid adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Loss and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [5].

ARID1A is altered in 2.53% of gastrointestinal stromal tumor patients with ARID1A Loss present in 0.44% of all gastrointestinal stromal tumor patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

ARID1A is altered in 3.1% of soft tissue sarcoma patients with ARID1A Loss present in 0.38% of all soft tissue sarcoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain ARID1A Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 9.89% of malignant ovarian epithelial tumor patients with ARID1A Loss present in 0.23% of all malignant ovarian epithelial tumor patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for malignant ovarian epithelial tumor, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and malignant ovarian epithelial tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

ARID1A is altered in 27.98% of bladder urothelial carcinoma patients with ARID1A Loss present in 0.21% of all bladder urothelial carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ARID1A is altered in 7.88% of non-small cell lung carcinoma patients with ARID1A Loss present in 0.07% of all non-small cell lung carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 10.67% of melanoma patients with ARID1A Loss present in 0.05% of all melanoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

ARID1A is altered in 5.83% of head and neck squamous cell carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Loss and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [5].

ARID1A Loss is an inclusion criterion in 2 clinical trials for ovarian clear cell adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 6.55% of small cell lung carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A Loss and small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

ARID1A is altered in 56.42% of malignant ovarian clear cell tumor patients with ARID1A Loss present in 1.33% of all malignant ovarian clear cell tumor patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 4.66% of mature T-cell and NK-cell non-hodgkin lymphoma patients with ARID1A Loss present in 1.23% of all mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A is altered in 2.89% of uveal melanoma patients with ARID1A Loss present in 0.87% of all uveal melanoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 1.64% of synovial sarcoma patients with ARID1A Loss present in 0.85% of all synovial sarcoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 14.85% of esophageal adenocarcinoma patients with ARID1A Loss present in 0.75% of all esophageal adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 9.62% of ampulla of vater carcinoma patients with ARID1A Loss present in 0.69% of all ampulla of vater carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 13.12% of esophageal carcinoma patients with ARID1A Loss present in 0.62% of all esophageal carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 4.52% of mantle cell lymphoma patients with ARID1A Loss present in 0.58% of all mantle cell lymphoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A is altered in 20.95% of malignant female reproductive system neoplasm patients with ARID1A Loss present in 0.41% of all malignant female reproductive system neoplasm patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 18.58% of biliary tract carcinoma patients with ARID1A Loss present in 0.38% of all biliary tract carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 15.65% of malignant esophagogastric neoplasm patients with ARID1A Loss present in 0.34% of all malignant esophagogastric neoplasm patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 13.31% of follicular lymphoma patients with ARID1A Loss present in 0.31% of all follicular lymphoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 17.68% of cholangiocarcinoma patients with ARID1A Loss present in 0.24% of all cholangiocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 27.44% of urothelial carcinoma patients with ARID1A Loss present in 0.24% of all urothelial carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 11.05% of malignant intestinal neoplasm patients with ARID1A Loss present in 0.23% of all malignant intestinal neoplasm patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 9.08% of cancer patients with ARID1A Loss present in 0.22% of all cancer patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 26.58% of bladder carcinoma patients with ARID1A Loss present in 0.2% of all bladder carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 8.97% of pancreatic adenocarcinoma patients with ARID1A Loss present in 0.16% of all pancreatic adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 8.82% of pancreatic carcinoma patients with ARID1A Loss present in 0.16% of all pancreatic carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A is altered in 4.46% of high grade ovarian serous adenocarcinoma patients with ARID1A Loss present in 0.14% of all high grade ovarian serous adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 4.24% of anal carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ARID1A is altered in 7.14% of epithelioid sarcoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 18.64% of gastric adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 18.48% of gastric carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A is altered in 3.37% of leiomyosarcoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 18.48% of malignant gastric neoplasm patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 23.11% of malignant ovarian endometrioid tumor patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 16.3% of malignant small intestinal neoplasm patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

ARID1A is altered in 0.78% of osteosarcoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 36.29% of ovarian endometrioid adenocarcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for ovarian small cell carcinoma, hypercalcemic type, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and ovarian small cell carcinoma, hypercalcemic type as inclusion criteria, 1 is phase 1 (1 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 3.45% of rhabdoid tumor patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A is altered in 5.43% of sarcomatoid carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A is altered in 22.22% of urethral urothelial carcinoma patients [4].

ARID1A Loss is an inclusion criterion in 1 clinical trial for urethral urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A Loss and urethral urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

ARID1A Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].